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The effects of insulin-like growth factor I (IGF-I) on
the migration of two human breast cancer cell lines,
MCF-7 and MDA-231, were examined using a modified
Boyden chamber. 10 ng/ml was the optimal IGF-I con-
centration for stimulation of migration. The majority of
IGF-I-stimulated migration in both cell types was due to
chemotaxis. MCF-7 cells failed to migrate onmembranes
coated with gelatin or fibronectin and migrated only in
small numbers on laminin. In contrast, when vitronec-
tin- or type IV collagen-coated membranes were used,
the MCF-7 cells migrated in large numbers specifically
in response to IGF-I but not to 10% fetal calf serum,
epidermal growth factor, fibroblast growth factor, or
platelet derived growth factor-BB. An IGF-I receptor-
blocking antibody inhibited IGF-I-stimulated migration
in both cell types. In addition, a blocking antibody to the
avb5 integrin (a vitronectin receptor) inhibited migra-
tion of MCF-7 cells in response to IGF-I through
vitronectin but not through type IV collagen. Similarly,
blocking antibodies specific for a2 and b1 integrins sig-
nificantly inhibited migration of both cell types through
type IV collagen-coated membranes but not through
vitronectin-coated membranes. We conclude that: 1)
IGF-I stimulates migration of these two cell types
through the IGF-I receptor; 2) interaction of vitronectin
with the avb5 integrin or collagen with the a2b1 inte-
grin is necessary for the complete IGF-I response in
MCF-7 cells, and 3) because migration represents an in
vitro model for metastatic spread, integrins, extracellu-
lar matrix proteins, and IGF-I may play coordinated
roles in the metastasis of breast cancer in vivo.
Insulin-like growth factor I (IGF-I)1 has been shown to be a
mitogen for human breast cancer cells including the MDA-231
and MCF-7 cultured cell lines (1–3). The increased growth of
these cells in the presence of IGF-I requires the normal func-
tion of the IGF-I receptor and can be blocked by a monoclonal
antibody to this receptor, aIR-3 (4). Terranova et al. (5) first
reported on the correlation between malignant cells capable of
traversing a porous membrane coated with extracellular ma-
trix components and the ability of these cells to cause metas-
tases. Using modified Boyden chambers or monolayer wound-
ing migration assays, other authors have found that IGF-I can
stimulate migration in human melanoma cells (6), FG pancre-
atic carcinoma cells (7), arterial smooth muscle cells (8, 9), and
endothelial cells (10). Other chemoattractants, such as inter-
leukin-1 and -6 for breast cancer cells (11) and epidermal
growth factor (EGF) for FG cells (7), have also been demon-
strated to stimulate cellular migration in these assays.
The integrins are a superfamily of heterodimer cell surface
glycoprotein receptors composed of distinct a and b subunits
(12). The integrins were originally described as cell adhesion
receptors, but their functions in cell behavior including motility
and invasion and their interactions with classical growth factor
receptor signaling pathways have been increasingly recognized
in the past few years (13). Although integrins themselves do
not possess tyrosine kinase activity, activation of integrins by
cell adhesion (14) or anti-integrin antibodies (15) causes tyro-
sine phosphorylation of p125FAK and other cytoplasmic pro-
teins. The avb3 integrin, a vitronectin receptor, was recently
shown to associate with insulin receptor substrate-1 in fibro-
blasts after the cells were stimulated with 100 nM insulin (16),
a dose capable of activating IGF-I receptors (17). A connection
between EGF stimulation and the activation of the avb5 inte-
grin (another vitronectin receptor) with cell migration has also
been described in pancreatic cancer cells (7). Our work began
with the hypothesis that IGF-I would stimulate migration of
MDA-231 and MCF-7 cells, which we have demonstrated uti-
lizing microwell Boyden chambers. We have characterized the
conditions required for optimal migration to IGF-I in these two
cell lines. This has led to the conclusion that the integrins
expressed by the cells play a key role in mediating the effect of
IGF-I to stimulate migration.
MATERIALS AND METHODS
Cell Culture and Materials—The MCF-7 (estrogen receptor positive)
and MDA-231 (estrogen receptor negative) human breast carcinoma
cells were obtained from the Lineberger Cancer Center, University of
North Carolina. They were maintained in Dulbecco’s modified Eagle’s
medium/Ham’s F-12 medium (1:1) (DMEM/F-12, Life Technologies,
Inc.) containing 10% fetal bovine serum (Life Technologies, Inc.), pen-
icillin, and streptomycin and passaged once or twice weekly using
PBS-EDTA and trypsin. The MCF-7 cells were transferred into similar
media containing 10% calf serum (Colorado Serum Co., Denver) 7–10
days prior to use in an assay. IGF-I was from Bachem, and the anti-
IGF-I receptor monoclonal antibody aIR-3 was kindly provided by
David Clemmons (University of North Carolina). The 48-well modified
Boyden chamber and Costar porous polyvinylpyrrolidine-free polycar-
bonate membranes (pore size, 8 mm) were purchased from Neuro Probe
(Cabin John, MD). Membranes were coated by incubation at room
temperature overnight just prior to use with gelatin (100 mg/ml in 10
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mM acetic acid, Sigma), fibronectin (30 mg/ml in PBS, Sigma), type IV
collagen (25 mg/ml in 10 mM acetic acid, Sigma), vitronectin (5 mg/ml in
PBS, Collaborative Biomedical, Bedford, MA), or laminin (25 mg/ml in
PBS, Collaborative Biomedical). Some experiments utilized purified
monoclonal blocking anti-integrin antibodies against avb3 (clone
LM609, Chemicon, Temecula, CA), avb5 (clone P1F6, Becton Dickinson
Cellular Imaging Systems, San Jose, CA), a2 (clone P1E6, Becton
Dickinson), and b1 (clone mAb13, Becton Dickinson). Purified mouse
IgG (Becton Dickinson) was used as a control.
Migration Assays—The cells (at or near confluency) were trypsinized
and replated in fresh media 12–16 h prior to each assay. The morning
of each assay, the cells were dispersed with nonenzymatic cell dispers-
ant (Sigma), washed twice, and then suspended in phenol red-free
DMEM/F-12 containing 0.01% BSA (DMEM/BSA). The final cell den-
sity was estimated using a hemacytometer. Lower wells of the Boyden
chamber apparatus were loaded with DMEM/BSA with or without
IGF-I in most assays. Other chemoattractants (EGF, basic fibroblast
growth factor (bFGF), and platelet derived growth factor-BB (PDGF-
BB), all from R and D Systems, Minneapolis, MN) were also prepared in
DMEM/BSA. A coated membrane was then placed over the lower wells,
and the upper portion of the chamber containing the upper wells was
placed on top of the apparatus and secured. A 50-ml volume of cell
suspension containing 15,000–25,000 (MDA-231) or 40,000–60,000
(MCF-7) cells was added to each upper well. In some assays, the cells
were preincubated with aIR-3, control IgG, or anti-integrin monoclonal
antibodies (all at 25 mg/ml) for 30–60 min at room temperature just
prior to loading the chamber. In studies comparing directional to non-
directional migration, IGF-I (final concentration, 10 ng/ml) was added
to selected upper wells immediately before the assay. The loaded cham-
ber was placed in a 37 °C incubator enriched with 5% CO2. After 4 h, the
chamber was removed from the incubator and disassembled. Cells on
the upper surface were removed by scraping so that only cells that had
migrated through the membrane remained. The membrane was then
fixed with methanol, stained with Diff-Quik (Baxter, McGaw Park, IL),
and allowed to air dry on a glass slide. Cell counts were obtained by
counting all cells in two (MDA-231) or four (MCF-7) grids, using a
microscope fitted with a grid eyepiece at a total magnification of 1003.
All data presented are the means 6 standard deviation of quadruplicate
wells from three or more experiments.
Anti-integrin Immunoprecipitation—The cells were grown to 80%
confluency in two 10-cm dishes, dispersed with a nonenzymatic dispers-
ant, and then washed extensively with Hepes-buffered saline (150 mM
NaCl, 40 mM Hepes, pH 7.3) containing 1 mM each of CaCl2, MgCl2, and
MnCl2 (HBS-CMM). The cells were labeled in 2 ml of HBS-CMM con-
taining 1 mCi of Na125I (ICN Pharmaceuticals, Costa Mesa, CA) and 10
Iodobeads (Pierce) for 10 min at 25 °C. The labeled cells were then
washed in HBS-CMM four times and lysed by incubation at 4 °C for 30
min in 600 ml of HBS-CMM containing 100 mM n-octyl-glucoside and
protease inhibitors. The 125I-labeled cell lysates (35 ml) were incubated
with 1 ml of anti-integrin antiserum or 10 mg of monoclonal antibody in
a total volume of 100 ml of immunoprecipitation buffer at 4 °C over-
night. The immunoprecipitation buffer contains HBS-CMM with 25 mM
n-octylglucoside, 0.1% ovalbumin, and 10 mM EDTA. Polyclonal anti-
sera used were anti-a1, -a2, -a3, -a5, -av, -b1, -b3, and -b5 from
Chemicon. Monoclonal anti-a6 (GoH3, Cappel, Durham, NC) was also
used. Rabbit anti-rat IgG (Pierce) was added to samples being immu-
noprecipitated with anti-a6. 6 mg of protein A linked to agarose beads
(Sigma) were added, and the incubations were then extended for an
additional 2 h. The beads were pelleted and washed 5 times in the
immunoprecipitation buffer and once in HBS-CMM. The antigen-anti-
body complexes were released by boiling the agarose beads in nonre-
ducing Laemmli sample buffer and resolved by 6% SDS-polyacrylamide
gel electrophoresis. The precipitated proteins were visualized by auto-
radiography of the fixed and dried gels.
RESULTS
IGF-I Stimulates Migration of MDA-231 and MCF-7 Cells—
Initial assays were performed using gelatin-coated membranes
to promote cell attachment to determine if IGF-I had any effect
on migration of these cell lines. Six separate assays demon-
strated that the MDA-231 cells increased migration by 2.2. 6
0.6-fold in response to IGF-I compared with DMEM/BSA alone.
The MDA-231 cells would also migrate toward IGF-I through
membranes coated with fibronectin, vitronectin, and type IV
collagen (Fig. 1). In contrast, the MCF-7 cells failed to migrate
through gelatin or fibronectin. Immunoprecipitation studies
(Fig. 2) showed that the MCF-7 cells have proportionately
higher amounts of the avb5 integrin vitronectin receptor than
do the MDA-231 cells as well as an abundance of the a2b1
collagen/laminin receptor. In agreement with these findings,
MCF-7 cells did migrate through membranes coated with
vitronectin or type IV collagen. (Fig. 1) Significantly, the
MCF-7 cells migrated only in response to IGF-I, not to DMEM/
BSA or 10% fetal bovine serum. Dose-response assays done
with both cell types established that 10 ng/ml was an optimal
concentration for stimulation of migration (data not shown). To
investigate the specificity of IGF-I’s capacity to stimulate mi-
gration, assays were performed on vitronectin-coated mem-
branes with EGF, bFGF, and PDGF-BB (Fig. 3), all of which
have been shown to stimulate migration in other cell types.
Neither bFGF nor PDGF-BB stimulated migration to a degree
comparable with that caused by IGF-I in either cell type. How-
ever, EGF did stimulate migration (3.5 6 0.3-fold) in MDA-231
cells similar to that seen with IGF-I (3.4 6 0.5-fold). In con-
trast, the MCF-7 cells migrated minimally to EGF (10–100
ng/ml) with only 5–25 cells/well compared with a range of
110–180 cells/well in response to IGF-I on vitronectin-coated
membranes. Because others have reported that laminin ar-
rested migration of MCF-7 cells on glass coverslips (18), we
performed simultaneous assays in two identical Boyden cham-
bers to compare IGF-I stimulated migration on vitronectin
versus laminin. With MCF-7 cell migration to IGF-I through
vitronectin assigned a relative value of 100%, migration
through laminin to IGF-I was reduced to 18 6 8%.
The Stimulated Migration Is Directional and Is Inhibited by
Anti-IGF-I Receptor Antibody—We next examined the relative
contributions of increased random movement (chemokinesis)
versus directional migration toward a concentration gradient of
IGF-I (chemotaxis). We performed checkerboard analyses in
which IGF-I (10 ng/ml) was added to either the lower wells
only, the upper wells only, both sets of wells, or neither. As
shown in Fig. 4, the addition of IGF-I to the upper well or to
both wells led to significantly less migration compared with
that observed when IGF-I was present in the lower wells only.
This was especially true for the MCF-7 cells, where migration
was reduced by over 75% by adding IGF-I directly to the cell
suspension rather than to the lower wells only. These experi-
ments demonstrated that IGF-I stimulated a primarily chemo-
FIG. 1. Migration of MDA-231 and MCF-7 cells: effects of dif-
ferent extracellular matrix proteins. The stimulatory effect of
IGF-I (10 ng/ml) on migration of these two cell lines is illustrated. The
number of cells indicated is the mean 6 S.D. counted per well in
multiple assays with either no IGF-I (open bars) or with IGF-I (filled
bars) in the lower wells only. The membranes were coated with gelatin
(G), fibronectin (Fn), vitronectin (Vn), or type IV collagen (Col). Impor-
tantly, the MCF-7 cells migrated only when the membrane was coated
with vitronectin or collagen and only when IGF-I was present.
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tactic response in both cell types. We investigated the role of
the IGF-I receptor in IGF-I-mediated chemotaxis by preincu-
bating the cells with aIR-3, a monoclonal IGF-I receptor-block-
ing antibody. Compared with the insignificant inhibition asso-
ciated with a murine IgG control, preincubation with aIR-3 led
to dramatic reductions in migration to IGF-I (Fig. 5). The
MDA-231 cells displayed a 65 6 10% reduction in migration;
the MCF-7 cells displayed a 91 6 6% decrease.
Anti-integrin Monoclonal Antibodies Inhibit IGF-I-stimu-
lated Chemotaxis of MCF-7 Cells—Because a membrane coat-
ing of either vitronectin or type IV collagen was necessary for
optimal IGF-I-stimulated migration, we sought to elucidate the
role of integrin receptors in this process. Immunoprecipitation
studies clearly showed that the MCF-7 cells have an abundance
of the a2b1 collagen/laminin receptor and the avb5 vitronectin
receptor (Fig. 2). We investigated the contributions of these
integrins by using monoclonal anti-integrin antibodies with
FIG. 2. Immunoprecipitation of breast carcinoma cell inte-
grins. To determine the presence and identity of integrin receptors on
the surface of the MCF-7 (A) and MDA-231 (B) cells, proteins on the
surfaces of intact cells were labeled with Na125I, and the labeled cells
were lysed and immunoprecipitated with specific antibodies directed
against integrin a or b subunits, as indicated beneath each lane. The
immunoprecipitates were resolved under nonreducing conditions on 6%
SDS-polyacrylamide gels. Autoradiographs of the dried gels are shown.
The arrows indicate the locations in the gels of the integrin subunits.
Because a and b integrin subunits are tightly associated until SDS-
polyacrylamide gel electrophoresis, an antibody against a given a or b
subunit will precipitate both subunits. In both cell lines the a2b1 and
a3b1 collagen/laminin receptors are abundant. The abundance of the
aVb5 vitronectin-binding integrins is greatest in the MCF-7 cells. No
aVb3 integrins were detected in either cell line.
FIG. 3. MDA-231 and MCF-7 cells vary in their responses to
chemoattractants. The effect of IGF-I on stimulation of migration
through vitronectin-coated membranes was compared with that of
other chemoattractants. Each is compared with the response of the cells
to IGF-I (10 ng/ml) in the same assay, which is assigned an arbitrary
value of 100%. EGF (10 ng/ml) elicited a response similar to that of
IGF-I in the MDA-231 cells. The effects of bFGF (20 ng/ml) and
PDGF-BB (10 ng/ml) were less pronounced. In contrast, the MCF-7 cells
(hatched bars) had a significant response only to IGF-I.
FIG. 4. Directional migration of MCF-7 and MDA-231 cells. The
graph depicts the effects on MDA-231 (open bars) and MCF-7 (hatched
bars) cell migration of adding IGF-I (10 ng/ml) to either the upper
chamber, lower chamber, neither chamber, or both chambers and was
performed as described under “Materials and Methods.” The number of
migrated cells when IGF-I was present in the lower well only is as-
signed a relative value of 100% and is a measure of chemotaxis. Migra-
tion in response to the addition of IGF-I to only the upper wells or to
both wells is a measure of chemokinesis, stimulation of migration in the
absence of a concentration gradient. For both cell lines, IGF-I is more
potent in stimulating migration when there is a positive concentration
gradient toward which the cells migrate.
FIG. 5. Inhibition of chemotaxis by an IGF-I receptor antibody.
Chemotaxis in response to IGF-I was determined in the presence and
the absence of the IGF-I receptor blocking antibody a-IR3 or control
mouse IgG at 25 mg/ml. Taking the total number of migrated cells (in
response to IGF-I, 10 ng/ml) with no added antibody as 100%migration,
a-IR3 reduced migration of MDA-231 cells (open bars) to 36 6 12%,
whereas nonspecific mouse IgG had a minimal effect. This effect was
more pronounced with the MCF-7 cells (hatched bars), where migration
was reduced to 9 6 5% by a-IR3.
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well defined functional blocking properties (19–22). As shown
in Fig. 6A, preincubation with the anti-avb5 antibody caused a
70% decrease in IGF-I-stimulated migration through vitronec-
tin, whereas the effect of the antibodies against avb3, a2, and
b1 were minimal. In Fig. 6B, the results of migration assays
utilizing membranes coated with type IV collagen are summa-
rized. The antibody against a2, which specifically blocks the
a2b1 integrin, and the antibody against b1, which blocks sig-
naling by multiple b1 integrins including both the a2b1 and
the a3b1 collagen receptors, had the most profound inhibitory
effects. This was not a nonspecific toxic effect of these antibod-
ies on the MCF-7 cells, because neither had an effect on cells
migrating through vitronectin in response to IGF-I (Fig. 6A).
DISCUSSION
This is the first report to our knowledge on the effects of
IGF-I on the chemotaxis of human breast cancer cells. Al-
though the potency of IGF-I to stimulate mitosis of human
breast cancer cells was established over a decade ago (2), its
ability to induce chemotaxis in these cells has not previously
been studied. The initial process in the metastatic spread of
breast carcinomas involves the invasion of malignant cells
through the extracellular matrix of a basement membrane
followed by their migration into lymphatic or vascular chan-
nels. IGF, synthesized by surrounding stromal cells, has been
implicated in the development of tumors from breast cancer
cells seeded into nude mice (4). The modified Boyden chamber
assays allow us to examine the cellular processes of invasion
and migration and provide a valid in vitro model of the in vivo
process of metastatic spread (5), which is responsible for nearly
all of the mortality from breast cancer (23). In addition, the
Boyden chamber assays avoid any confusion of migration with
proliferation even in these rapidly proliferating transformed
cells by virtue of its 4-h duration. It also allows for precise
definition of the extracellular matrix proteins over which the
cells migrate.
We selected the MCF-7 and MDA-231 cell lines because their
increased growth in response to IGF-I has been well character-
ized (1–3) and because they were both isolated from metastatic
sites. Other authors have used the MDA-231 cells for study
based on their high degree of invasiveness (24). Our results are
in agreement with this, because we found that the MDA-231
traversed every membrane coating used, including gelatin, fi-
bronectin, laminin, vitronectin, and type IV collagen. Further-
more, the MDA-231 cells migrated in the absence of growth
factors and demonstrated chemotaxis toward bFGF, EGF,
PDGF-BB, and 10% fetal bovine serum as well as toward IGF-I.
In contrast, migration of the MCF-7 cells was found to have
more specific requirements. The MCF-7 cells migrated only in
response to IGF-I not toward a negative control, 10% fetal
bovine serum, or three other growth factors. These other
growth factors, EGF, bFGF, and PDGF-BB, have each been
shown to be capable of inducing increased migration in other
cell types (7, 8, 25). Furthermore, the MCF-7 cells showed a
brisk response to IGF-I only when migrating through mem-
branes coated with vitronectin or type IV collagen. While not
causing the complete arrest of MCF-7 cell migration reported
by other investigators using laminin-coated glass coverslips
(18), the use of membranes coated with laminin in our assays
led to dramatic reductions in cell migration compared with
vitronectin or type IV collagen. Furthermore, there was no
detectable migration of MCF-7 cells on membranes coated with
gelatin or fibronectin. The marked differences in conditions
required for migration between these two cell lines may be
related to their differences in estrogen receptor status. Studies
using estradiol and anti-estrogens to modify the migration
response of MCF-7 cells will be required to determine the
dependence of this response on estrogen receptor activation.
Alternatively, the observed differences in growth factor re-
sponses between the two cell lines may be due to the highly
undifferentiated state of the MDA-231 cells compared with the
MCF-7 line, which retains some epithelial characteristics. The
two cell lines also have differences in IGF-binding protein
expression (26). Because IGF-binding proteins can have direct,
integrin-mediated effects on cell migration (27) as well as ef-
fects on IGF interactions with the IGF-I receptor (17), further
studies into the effects of IGF-binding proteins on IGF-stimu-
lated cell migration are warranted.
The results of the checkerboard analyses (Fig. 4) established
that the majority of increased migration we observed in re-
sponse to IGF-I was due to chemotaxis, directional migration
toward a higher concentration of a solubilized chemoattractant.
The finding that a positive concentration gradient of IGF-I,
rather than its mere presence, is necessary for optimal migra-
tion may have important physiologic implications. IGF synthe-
FIG. 6. IGF-I-stimulated migration of MCF-7 cells: effects of
anti-integrin antibodies. IGF-I-stimulated (10 ng/ml) chemotaxis
was determined in the presence and the absence of monoclonal anti-
integrin blocking antibodies (25 mg/ml) against aVb3 (clone LM609,
Chemicon), aVb5 (clone P1F6, Becton Dickinson), a2 (clone P1E6, Bec-
ton Dickinson), and b1 (clone mAb13, Becton Dickinson) and control
nonimmune mouse IgG. Experiments were performed utilizing mem-
branes coated with either vitronectin (A) or type IV collagen (B). Mi-
gration in the absence of antibodies was taken as 100%. Through
vitronectin-coated membranes (A), anti-aVb5 inhibited migration by 70
6 18%, whereas the other antibodies and IgG had small effects. In
contrast, through collagen-coated membranes, both anti-a2 and anti-b1
had major effects, reducing migration by 63 6 5% and 96 6 6%,
respectively, whereas anti-aVb5 and IgG had minimal effects.
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sis in tumor specimens has been shown to originate from sur-
rounding stromal cells, suggesting the presence of IGF
concentration gradients in breast carcinomas in vivo. The
blocking antibody to the IGF-I receptor, aIR-3, has previously
been shown to be capable of inhibiting the increased growth of
the MDA-231 and MCF-7 cells associated with their exposure
to IGF-I (28). Therefore, it was not surprising that preincuba-
tion of the cells with this antibody would also markedly limit
their migratory response to IGF-I. We performed these exper-
iments to be certain that the chemotaxis induced by IGF-I was
an IGF-I receptor-dependent phenomenon.
It has recently become clear that the integrins function as
true receptors, transmitting signals to the cell interior upon
ligation by extracellular matrix components (29). Our results
demonstrate that both integrin receptors and IGF-I receptors
are involved in IGF-I-stimulated migration of MCF-7 cells. The
immunoprecipitation studies (Fig. 2) demonstrated that the
MCF-7 cell line has a proportionately higher amount of the
avb5 integrin, a vitronectin receptor, compared with the MDA-
231 cells. The predominant vitronectin receptor expressed by
the MCF-7 cells is the avb5 integrin, and preincubation of
these cells with a blocking antibody to avb5 markedly reduced
their migratory response to IGF-I through vitronectin-coated
membranes (Fig. 6A). As predicted, cells preincubated with the
same anti-avb5 antibody were not significantly affected when
migrating toward IGF-I through type IV collagen, confirming
the specificity of the requirement for avb5 for migration on
vitronectin (Fig. 6B).
The a2b1 integrin can serve to mediate IGF-I-stimulated
migration when the cells migrate through collagen. The a2b1
and a3b1 integrins are both capable of binding to type IV
collagen but not to vitronectin. The antibody to the b1 subunit,
common to both receptors, produced the most significant inhi-
bition of migration when assays were conducted with mem-
branes coated with type IV collagen (Fig. 6B), almost eliminat-
ing the response to IGF-I. In addition, the anti-a2 antibody
inhibited migration on type IV collagen by 63%. Neither anti-
body had a significant effect on the MCF-7 cells migrating
through vitronectin (Fig. 6A), confirming that the requirement
for a2b1 (and possibly a3b1) functionality is specific for migra-
tion on type IV collagen in these cells.
We therefore conclude that integrins are activated during
the process of IGF-I-stimulated chemotaxis in breast cancer
cells. The identity of the integrin that is essential for cell
migration is specific to the particular extracellular matrix sub-
stance used. This is the first description of this association
between IGF-I receptor stimulation and integrin function in
breast cancer cells. Breast cancer tissues have been shown to
have altered patterns of integrin expression (30) and higher
numbers of IGF-I receptors (31) when compared with normal
breast tissue. It is likely that integrins are involved in the
response of these malignant cells to IGF-I, mediating their
ability to traverse basement membranes and metastasize.
The role of IGF-I in the stimulation of migration is an im-
portant area of study that heretofore has been relatively ne-
glected compared with the role of IGF-I in cellular growth and
proliferation. Although the precise mechanisms by which the
IGF-I receptor and integrin receptors interact are not yet
known, this area of study warrants continued investigation. If
the nature of the cross-talk between these two signaling sys-
tems can be elucidated, our understanding of malignant behav-
ior will be greatly enhanced.
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